Palbociclib and Letrozole in Advanced Breast Cancer.

By R. Finn, Miguel Martín, H. Rugo, Stephen E. Jones, S. Im, K. Gelmon, N. Harbeck, O. Lipatov, J. Walshe, S. Moulder and 5 more. New England Journal of Medicine, 2016

2,471 citations recorded by the source corpus.

Subfields: Cancer Research, Oncology, Pulmonary and Respiratory Medicine

View Paper: https://www.semanticscholar.org/paper/a9c2ee76bbb1cd253465c878572dc5734d73d0d3

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Oncology

1. M. Jorge Cardoso
2. Larry Norton

Citations in the corpus

• ESMO Clinical Practice Guideline for the diagnosis, staging and treatment of patients with metastatic breast cancer. (2021, background): “The toxicity pro fi les of these three drugs are slightly different, 25-30 and patients who develop severe toxicity characteristic of one CDK4/6 inhibitor may switch to a different CDK4/6 inhibitor.”
• 5th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 5) (2020, background): “The last 2 years have seen the establishment of cyclindependent kinase (CDK)4/6 inhibitors combined with endocrine therapy (ET) as the standard of care for ER-positive/HER2-negative ABC in view of the OS benefit seen in several trials,(36-42) both in the first- and second-line settings, substantial ”
• CCRK is a novel signalling hub exploitable in cancer immunotherapy (2018, neutral): “The enthusiasm for CDK inhibitors was thus dampened, until a relatively selective CDK4/6 inhibitor Palbociclib was recently approved by the FDA for treating HR and HER2 metastatic breast cancer (Finn et al., 2016).”
• Overall Survival with Palbociclib and Fulvestrant in Advanced Breast Cancer (2018, neutral): “Cyclophosphamide 13 (5) 9 (5) 23 (18) 8 (6) 4 (4) 8 (9)”
• Updated results from MONALEESA-2, a phase III trial of first-line ribociclib plus letrozole versus placebo plus letrozole in hormone receptor-positive, HER2-negative advanced breast cancer (2018, neutral): “Hematologic AEs continue to represent the most common grade 3/4 AEs in the ribociclib plus letrozole arm, consistent with other CDK4/6 inhibitors [9, 10].”